TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs

Group 1 - Orchestra BioMed Holdings Inc. is recognized as a promising biotech penny stock, with TD Cowen initiating coverage with a Buy rating and a $15 price target, highlighting its leadership in cardiovascular device innovation [1] - The company's royalty-based model is supported by two significant programs: AVIM for hypertension and Virtue SAB for atherosclerotic disease, addressing substantial market gaps [1] - Orchestra BioMed is approaching critical data and commercialization milestones that could be transformative, aided by partnerships with blue-chip companies and high-margin potential [1] Group 2 - The company is advancing two pivotal programs, with the Virtue Trial enrollment starting in Q3 2025, comparing Virtue SAB against AGENT paclitaxel-coated balloon for treating coronary in-stent restenosis, targeting enrollment completion by mid-2027 [2] - The BACKBEAT global pivotal study for AVIM Therapy has seen recent FDA-approved protocol enhancements, expanding the eligible patient pool over 24-fold, with enrollment expected to complete by mid-2026 [2] Group 3 - Orchestra BioMed has expanded its partnership with Medtronic to develop AVIM Therapy-enabled leadless pacemakers, while retaining all development and distribution rights for Virtue SAB across all indications despite Terumo holding a right of first refusal for certain transactions [3][4]